SilverHawk EXL catheter launched in the US:
This article was originally published in Clinica
Executive Summary
FoxHollow Technologies has launched its SilverHawk EXL plaque excision device in the US. The product is designed to remove atherosclerotic tissue that blocks arteries in the lower leg of patients suffering from peripheral artery disease (PAD). It is an advance on the currently-marketed SilverHawk product line in that it has a lengthened nosecone and includes Redwood City, California-based FoxHollow's micro efficient compression (MEC) technology - laser-drilled micro vent holes in the tip of the catheter. These vents provide more space for the collection of tissue in the tip of the device. It is expected to be CE marked for sale in Europe by the end of this quarter, and will be marketed as part of the firm's integrated commercial effort with Plymouth, Minnesota-based ev3, once the firms' merger closes at the end of this year (see Clinica No 1266, p 3).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.